Last updated: September 7, 2026
The acetaminophen/bუტalbital/caffeine/codeine phosphate combination is a mature, low-growth prescription headache product sold primarily as a generic oral capsule. Its commercial value is constrained by generic price competition, opioid controls, dependence concerns, and migration toward migraine-specific therapies. The combination has limited patent protection, no biosimilar exposure, and a high probability of continued price erosion. Product-level revenue is generally not disclosed because manufacturers report it within broader generic portfolios.
What is the acetaminophen, butalbital, caffeine, and codeine phosphate product?
The product is a fixed-dose oral combination used for tension-type or muscular-contraction headaches. A commonly marketed U.S. strength contains:
| Ingredient |
Common amount per capsule |
Commercial role |
| Acetaminophen |
300 mg |
Analgesic |
| Butalbital |
50 mg |
Barbiturate sedative |
| Caffeine |
40 mg |
Analgesic adjuvant |
| Codeine phosphate |
30 mg |
Opioid analgesic |
Formulations and labeling can vary by manufacturer. The product is commonly associated with the legacy brand Fioricet with Codeine and generic equivalents. It is distinct from Fioricet, which does not contain codeine.
The FDA-approved labeling warns about sedation, dependence, respiratory depression, hepatotoxicity from excessive acetaminophen, and medication-overuse headache. Codeine is an opioid, while butalbital is a barbiturate. The combination therefore carries higher controlled-substance and safety burdens than acetaminophen/butalbital/caffeine products without codeine (FDA, 2023a).
How large is the market for this four-drug combination?
The market is established but commercially small relative to major migraine and pain categories. Public manufacturers generally do not report sales separately for the four-drug combination. Market size is better assessed through prescription volume, paid claims, reimbursement, and generic manufacturer participation than through branded pharmaceutical revenue.
Demand is supported by:
- Longstanding physician familiarity.
- Low generic acquisition cost.
- Use in primary care and neurology.
- Patient familiarity with butalbital-containing products.
- Coverage under many commercial and government formularies.
Demand is limited by:
- Opioid stewardship programs.
- Barbiturate dependence and withdrawal risk.
- Restrictions on controlled-substance prescribing.
- Medication-overuse headache concerns.
- Availability of triptans, gepants, ditans, and preventive CGRP therapies.
- Clinical preference for non-opioid and migraine-specific treatment.
The product remains relevant in a narrow treatment segment but is not positioned for material unit or revenue growth.
What is the financial trajectory for acetaminophen/butalbital/caffeine/codeine?
The financial trajectory is mature to declining in value per prescription, with volume relatively stable or declining depending on payer and prescriber restrictions.
| Financial driver |
Direction |
Effect |
| Generic price |
Downward |
Compresses manufacturer revenue and gross margin |
| Prescription volume |
Flat to downward |
Limits market expansion |
| Wholesale acquisition cost |
Competitive |
Reduces pricing power |
| Controlled-substance compliance |
Upward cost pressure |
Raises operating and distribution costs |
| Formulary restrictions |
Mixed |
Can reduce utilization or shift volume to preferred generics |
| Alternative migraine therapies |
Negative |
Reduces long-term prescribing |
| Shortages or manufacturer exits |
Potentially positive for remaining suppliers |
Can temporarily improve pricing |
Manufacturers with approved generic versions can generate recurring cash flow through relatively inexpensive production and established distribution. The product is unlikely to generate the margin profile associated with a patented branded medicine. Its economics depend on manufacturing scale, supply reliability, wholesaler access, and the number of active generic competitors.
Revenue may temporarily increase for a supplier during a competitor shortage or product discontinuation. That benefit is usually unstable because additional manufacturers can re-enter or increase supply. Sustained price expansion would require a supply disruption, a regulatory change, or a significant reduction in competing manufacturers.
No major branded manufacturer publicly identifies this four-drug product as a material standalone revenue contributor. Financial exposure is therefore concentrated in generic portfolios rather than in a single commercial franchise.
When does this product lose exclusivity?
The clinically relevant exclusivity period has already expired. The combination is based on legacy active ingredients and has been commercially available for decades.
| Exclusivity category |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No current meaningful protection |
| Reference-product exclusivity |
Expired or commercially irrelevant |
| Composition-of-matter patent |
No meaningful active protection identified |
| Generic substitution |
Established |
| Biosimilar exclusivity |
Not applicable |
The key commercial event was not a recent patent expiration. Generic competition became possible long ago through the established regulatory pathways for these products.
What patents protect acetaminophen, butalbital, caffeine, and codeine phosphate?
The four-drug combination has a weak patent estate. The active ingredients are old, and any historical composition or formulation patents associated with legacy products would generally have expired.
The principal intellectual-property risks are limited to:
- Later-developed formulation patents.
- Manufacturing-process patents.
- Packaging or abuse-deterrence technology.
- Narrow patents covering a specific dosage strength or release profile.
- Trademarks and trade dress associated with a branded product.
These rights do not normally prevent ordinary immediate-release generic competition. A manufacturer seeking approval for the standard immediate-release combination would generally face a regulatory and manufacturing task rather than a significant patent barrier.
What is the Orange Book status of the product?
The FDA Orange Book is the primary U.S. source for approved drug products, therapeutic-equivalence evaluations, patent listings, and exclusivity data (FDA, 2024).
For this combination, the practical Orange Book assessment is:
- Generic products are the primary commercial supply.
- Active patent protection is not the principal barrier to entry.
- Any listed patents must be reviewed at the specific reference-product and dosage-form level.
- A lack of current patent protection does not eliminate regulatory requirements for an ANDA.
- Therapeutic-equivalence codes and approved strengths may differ among manufacturers.
The relevant distinction is between an approved generic product and a listed patent. A product can have no meaningful patent barrier while still requiring bioequivalence, manufacturing, labeling, controlled-substance compliance, and FDA approval.
Are Paragraph IV challenges likely?
Paragraph IV litigation risk is low because the product is already a mature generic market with limited apparent patent protection. Paragraph IV certifications matter only when an ANDA applicant challenges a listed patent. If no enforceable patent is listed for the targeted reference product, a Paragraph IV challenge is not the principal entry mechanism.
Generic applicants may instead rely on:
- Paragraph I certifications where no patent information is listed.
- Paragraph II certifications where listed patents have expired.
- Paragraph III certifications with launch after patent expiration.
- Paragraph IV certifications for any remaining formulation or method-of-use patent.
The likely competitive threat is ordinary generic entry and additional generic filings, not a high-value patent dispute.
What formulation patents protect the combination?
Standard immediate-release capsules have limited defensibility. A formulation patent would require a meaningful technical distinction, such as:
- Modified release of codeine or butalbital.
- Abuse-deterrent delivery.
- Reduced acetaminophen exposure.
- Improved stability or dissolution.
- A distinct capsule or tablet architecture.
- A fixed ratio supported by clinical or pharmacokinetic data.
A manufacturer could obtain protection for a new delivery system, but that would protect the improved formulation rather than the basic four-drug combination. Such a product would also face reimbursement and adoption challenges because prescribers can use inexpensive immediate-release generics.
What method-of-use patents cover the product?
Potential method-of-use claims could address a defined headache subtype, dosing schedule, patient population, or treatment sequence. Their commercial value is limited because:
- The active ingredients are already used for established headache indications.
- Generic labels may use carve-outs for patented indications.
- Physicians can prescribe generic products for non-patented uses.
- Medication-overuse and opioid-safety concerns narrow the addressable population.
A method-of-use patent would be more relevant to a reformulated or clinically differentiated product than to the existing generic capsule.
Which companies are challenging the product or competing with it?
Competition is primarily from generic manufacturers, contract manufacturers, and portfolio distributors. Publicly disclosed product-level market shares are limited.
The main competitive groups are:
- Suppliers of acetaminophen/butalbital/caffeine/codeine capsules.
- Suppliers of Fioricet-equivalent products without codeine.
- Manufacturers of butalbital/acetaminophen combinations.
- Migraine-specific drug companies selling triptans, gepants, ditans, and CGRP antibodies.
- Low-cost analgesic manufacturers selling acetaminophen-based alternatives.
The closest pharmacologic competitor is acetaminophen/butalbital/caffeine without codeine. That product avoids opioid exposure but retains the dependence and medication-overuse concerns associated with butalbital.
How does the four-drug product compare with Fioricet without codeine?
| Factor |
Four-drug product |
Fioricet-type product without codeine |
| Active ingredients |
Acetaminophen, butalbital, caffeine, codeine |
Acetaminophen, butalbital, caffeine |
| Opioid exposure |
Yes |
No |
| Controlled-substance burden |
Higher |
Lower, though butalbital remains controlled or regulated depending on jurisdiction |
| Dependence risk |
Opioid and barbiturate risks |
Barbiturate risk |
| Prescribing restrictions |
More extensive |
Generally less extensive |
| Generic competition |
High |
High |
| Long-term market outlook |
More exposed to opioid stewardship |
Still exposed to butalbital concerns |
| Position against migraine-specific drugs |
Weak |
Weak to moderate in selected patients |
The codeine-containing product has a narrower commercial future because it combines two dependence-associated ingredients. The non-codeine product may retain broader use where clinicians avoid opioids, although it remains vulnerable to newer migraine therapies.
What FDA regulatory issues affect the market?
The FDA-approved label carries warnings for addiction, abuse, misuse, respiratory depression, sedation, and potentially fatal overdose when opioids are combined with benzodiazepines, alcohol, or other central nervous system depressants (FDA, 2023a).
Key regulatory factors include:
- Controlled-substance recordkeeping.
- Prescription monitoring programs.
- State-specific opioid limits.
- Manufacturer quota and distribution controls.
- Pharmacist refusal or additional verification.
- Acetaminophen safety limits.
- Labeling requirements for opioid products.
- Manufacturing and quality-system compliance.
Codeine combination products have historically occupied different scheduling positions depending on codeine content and formulation. The exact schedule must be confirmed against the current federal and state classification applicable to the product and strength (DEA, 2024).
What patent litigation and settlement agreements affect the product?
No major, high-value U.S. patent settlement is central to the current commercial position of this legacy combination. The market is driven by generic availability and controlled-substance regulation rather than by an active branded patent dispute.
Potential litigation exposure is more likely to arise from:
- Product liability claims.
- Failure-to-warn allegations.
- Manufacturing deviations.
- Controlled-substance distribution practices.
- Generic labeling or quality disputes.
- False-claims or reimbursement matters.
These risks can affect manufacturers even when patent risk is minimal.
Is there biosimilar risk for this product?
Biosimilar risk is not applicable. The product is a small-molecule oral combination, not a biologic. Competitive entry occurs through generic-drug pathways, including ANDAs and, for certain differentiated products, 505(b)(2) applications.
A 505(b)(2) applicant could pursue a new formulation, dosage form, or clinical positioning. That route may create a differentiated product but would not remove the price pressure from existing immediate-release generics.
What manufacturing and geographic barriers exist?
Manufacturing barriers are moderate operationally and low technologically. The ingredients are established, but codeine and butalbital require controlled-substance sourcing, inventory controls, security, recordkeeping, and distribution compliance.
Relevant barriers include:
- Access to qualified active pharmaceutical ingredient suppliers.
- DEA registration and quota management.
- Segregated controlled-substance handling.
- Finished-dose testing and stability data.
- Reliable capsule filling and packaging.
- FDA inspection readiness.
- State distribution requirements.
- Import and export restrictions.
Geographic protection is limited. U.S. market access depends on FDA approval and controlled-substance compliance. Other countries apply different rules to codeine, butalbital, acetaminophen, and fixed-dose combinations. Codeine availability and scheduling vary substantially by jurisdiction. A U.S. approval does not create automatic international commercial access.
What generic launch scenarios are most likely?
Base case
Existing generic suppliers retain the market, with gradual unit decline and continuing price pressure. Prescribing shifts toward non-opioid analgesics and migraine-specific products.
Supply-constrained case
One or more manufacturers exit because of low margins, compliance costs, or API constraints. Remaining suppliers obtain temporary volume and pricing benefits.
Accelerated-decline case
Payers, health systems, and state regulators expand restrictions on opioid and barbiturate headache products. Prescriptions shift to non-codeine butalbital products, triptans, gepants, or other migraine therapies.
Differentiated-product case
A company launches a modified-release or abuse-deterrent version. Commercial success would depend on clinical differentiation, reimbursement, and evidence that the formulation solves a recognized safety or adherence problem.
How strong is the patent estate and commercial position?
The patent estate is weak. The commercial position is durable only because the product has established demand, low manufacturing complexity, and physician familiarity.
| Category |
Assessment |
| Composition patents |
Weak or expired |
| Formulation protection |
Limited unless a differentiated product is developed |
| Method-of-use protection |
Narrow and difficult to monetize |
| Generic entry risk |
High |
| Biosimilar risk |
None |
| Regulatory burden |
Moderate to high |
| Pricing power |
Low |
| Revenue growth potential |
Low |
| Supply disruption upside |
Possible but temporary |
| Long-term market outlook |
Flat to declining |
Key Takeaways
- The acetaminophen/butalbital/caffeine/codeine phosphate combination is a mature generic product.
- Its common U.S. strength is 300 mg acetaminophen, 50 mg butalbital, 40 mg caffeine, and 30 mg codeine phosphate.
- The product has no meaningful current composition-of-matter exclusivity.
- Generic competition, not patent litigation, determines pricing and market access.
- Product-level revenue is not generally disclosed by manufacturers.
- Financial performance is likely flat to declining, with temporary upside during supply disruptions.
- Opioid controls, barbiturate dependence, medication-overuse headache, and newer migraine drugs constrain demand.
- Biosimilar competition is irrelevant because the product is a small-molecule combination.
- The main commercial opportunity is efficient generic supply, not premium pricing.
- A reformulated product could create new intellectual property but would face substantial reimbursement and adoption challenges.
FAQs
Is acetaminophen/butalbital/caffeine/codeine still commercially available?
Yes. The combination remains available through generic prescription products, although availability varies by manufacturer, pharmacy, state, and controlled-substance supply conditions.
Is Fioricet with codeine still patent protected?
The legacy combination does not have a commercially meaningful composition patent barrier. Any specific Orange Book patent listing must be evaluated against the precise reference product and dosage form.
Does codeine make this product more commercially vulnerable than Fioricet without codeine?
Yes. Codeine adds opioid-specific prescribing, dispensing, monitoring, and liability concerns. Those factors narrow demand relative to the non-codeine combination.
Can a company obtain a new patent on this drug combination?
A company may obtain patent protection for a novel formulation, release profile, manufacturing process, or defined use. A patent on the old immediate-release combination itself would face substantial validity and eligibility challenges.
What is the strongest substitute for this product?
The closest substitute is acetaminophen/butalbital/caffeine without codeine. For migraine-oriented treatment, triptans, gepants, ditans, and CGRP preventive therapies present a stronger long-term competitive threat.
References
-
Drug Enforcement Administration. (2024). Controlled substances schedules. U.S. Department of Justice. https://www.dea.gov/drug-information/drug-scheduling
-
U.S. Food and Drug Administration. (2023a). Fioricet with Codeine prescribing information. FDA. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Drug approval and databases. FDA. https://www.fda.gov/drugs/development-approval-process-drugs-industry
